1 | Ambrisentan | Ambrisentan [11] Ambrisentan; Ambrisentan - high dose; Ambrisentan - low dose; Ambrisentan 5 mg; Ambrisentan 5 mg film-coated tablets; Ambrisentan 5mg film-coated tablets [marketed product]; Ambrisentan plus spironolactone; Ambrisentan tablet; Bosentan, ambrisentan; Tadalafil and ambrisentan upfront combination therapy; Volibris® (ambrisentan); | [1] D07077 D07077 💬 |
[1] EDNRA 💬 |
Calcium signaling pathway [7] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 [7] 51, 84, 85, 86, 88, 210, 211 💬 |
2 | Ascorbic acid | 2l polyethylene glycol/ascorbic acid [5] 2l polyethylene glycol/ascorbic acid; Ascorbic acid; Ascorbic acid (vitamin c); Ascorbic acid (vitamin c) and alpha-tocopherol (vitamin e); Ascorbic acid vit c; | [1] D00018 D00018 💬 |
- |
- |
010 [8] 10, 97, 192, 206, 210, 211, 212, 298 💬 |
3 | Bosentan | Bosentan [18] Bosentan; Bosentan (tracleer); Bosentan 125 mg; Bosentan 62.5 mg; Bosentan administration; Bosentan and sildenafil; Bosentan group; Bosentan monohidrato; Bosentan monohydrat; Bosentan monohydrate; Bosentan mylan; Bosentan, ambrisentan; Device: nirs after bosentan administration; Device: tcd after bosentan administration; Duo-therapy with sildenafil + bosentan; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Sildenafil 20mg and bosentan 62.5mg; Sildenafil singly or in association with bosentan; | [2] D01227 D01227
D07538 D07538 💬 |
[2] EDNRA, EDNRB 💬 |
Calcium signaling pathway [9] Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬 |
4 | Methylprednisolone | Administration of rituximab and methylprednisolone [35] Administration of rituximab and methylprednisolone; Corticosteroid treatment (methylprednisolone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Infliximab, methylprednisolone, methotrexate; Interferon-beta-1a (avonex) plus methylprednisolone; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Intravenous methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methotrexate + methylprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone (mp); Methylprednisolone (mp) or prednisone (pred); Methylprednisolone (or other glucocorticoid); Methylprednisolone (solu-medrol); Methylprednisolone 1250 mg/24h x3 days; Methylprednisolone acetate; Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone mylan générique; Methylprednisolone or budesonide; Methylprednisolone or prednisolone; Methylprednisolone po; Methylprednisolone pulse; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Oral methylprednisolone 625 mg/24h x3 days; Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides; | [6] D00407 D00407
D00751 D00751
D00979 D00979
D05000 D05000
D05001 D05001
D05002 D05002 💬 |
[1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
002 [44] 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬 |
5 | Methylprednisolone hemisuccinate | Methylprednisolone hemisuccinate [1] Methylprednisolone hemisuccinate; | [1] D05000 D05000 💬 |
[1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [7] 13, 49, 50, 51, 53, 97, 211 💬 |
6 | Nitrogen | Device: perform three multiple breath nitrogen washout tests (n2-mbw-test) [3] Device: perform three multiple breath nitrogen washout tests (n2-mbw-test); Nitrogen; Procedure: functional hepatic nitrogen clearance; | [1] D00083 D00083 💬 |
- |
- |
005 [6] 5 , 6 , 17, 171, 211, 299 💬 |
7 | Oxandrolone | Oxandrolone [1] Oxandrolone; | [1] D00462 D00462 💬 |
[1] AR 💬 |
Oocyte meiosis [3] Oocyte meiosis, Pathways in cancer, Prostate cancer |
211 [2] 211, 285 💬 |
8 | Poractant alfa | - | [1] D08402 D08402 💬 |
- |
- |
211 [1] 211 💬 |
9 | Sildenafil | 20 mg sildenafil citrate by mouth [32] 20 mg sildenafil citrate by mouth; 5% sildenafil cream; Access program - sildenafil citrate, viagra, revatio; Bosentan and sildenafil; Duo-therapy with sildenafil + bosentan; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); G04be03- sildenafil - sildenafil (citrato); Mono-therapy with sildenafil; Oral sildenafil; Other: standard of care sildenafil; Sildenafil; Sildenafil (50 mg); Sildenafil (acute-1 hour); Sildenafil (as citrate); Sildenafil (revatio); Sildenafil (revatio) 20 mg tid; Sildenafil (subchronic-4 weeks); Sildenafil 20 mg tablets; Sildenafil 20mg; Sildenafil 20mg and bosentan 62.5mg; Sildenafil 40mg oral capsule; Sildenafil and losartan; Sildenafil by injection; Sildenafil citrate; Sildenafil citrate (uk-92,480); Sildenafil filmtabletten; Sildenafil singly or in association with bosentan; Sildenafil therapy; Sildenafilo; Sitaxsentan and sildenafil; Sodium tanshinone iia sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth; Tadalafil and sildenafil; | [2] D02229 D02229
D08514 D08514 💬 |
[1] PDE5A 💬 |
Metabolic pathways [3] Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
006 [17] 6 , 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬 |